Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/2209
Lack of Antiviral Activity of Darunavir against SARS-CoV-2
Sandra De Meyer.
Denisa Bojkova.
Jindrich Cinati.
Ellen Van Damme.
Christophe Buyck.
Marnix Van Loock.
Brian Woodfall.
Sandra Ciesek.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.04.03.20052548
Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100 M). Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 M). Overall, the data do not support the use of DRV for treatment of COVID-19.
www.medrxiv.org
2020
Artículo
https://www.medrxiv.org/content/10.1101/2020.04.03.20052548v1.full.pdf
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
1101277.pdf123.76 kBAdobe PDFView/Open